DNA Repair Drugs Market size is estimated at USD 8.2 billion in 2024 and is likely to exceed USD 48.2 billion by the end of 2037, expanding at over 14.6%% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of DNA repair drugs is assessed at USD 9.4 billion.
The advancements in DNA sequencing and the rising prevalence of cancer are some of the major factors boosting the DNA repair drugs market growth. For instance, according to the World Health Organization report, in 2022, an estimated 20 million new cancer cases were detected globally.
Several cancer research organizations including Cancer Research UK are investing heavily in research and development activities to develop advanced DNA repair drugs for effective patient care. PARP inhibitors are emerging as one of the effective technologies for the treatment of breast, prostate, and other types of cancer. Such developments are anticipated to double the profits of DNA repair drug producers in the coming years.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.6% |
|
Base Year Market Size (2024) |
USD 8.2 billion |
|
Forecast Year Market Size (2037) |
USD 48.2 billion |
|
Regional Scope |
|
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics)
Based on distribution channel, hospital pharmacies are projected to hold a dominant DNA repair drugs market share by 2037. Hospital pharmacies are equipped with skilled pharmacists and advanced therapeutic solutions for chronic disorders, also the high admission of patients to hospitals for advanced care makes these pharmacies the prime distribution channel for DNA repair drugs. Hospital pharmacists have specialized training and knowledge of complex medications, including DNA repair drugs that ensure proper handling and patient-specific dosing adjustments. Also, hospitals have advanced infrastructure and budgets which makes easy availability of DNA repair drugs in their pharmacies.
Drug Type (PARP Inhibitors, ATM Kinase Inhibitors, ATR Inhibitors, DNA-PK Inhibitors, BER Inhibitors, NER Inhibitors, Mismatch Repair (MMR) Inhibitors, Homologous Recombination (HR) Inhibitors, Non-Homologous End Joining (NHEJ) Inhibitors)
PARP inhibitors are anticipated to capture a high share in DNA repair drugs market throughout the forecasted period. PARP inhibitors are one of the most effective targeted cancer drugs used for the treatment of ovarian cancer in women. The increasing awareness of the role of PARP inhibitors in oncology coupled with ongoing research and development are driving their demand growth. For instance, in September 2022, Merck joined hands with Nerviano Medical Sciences S.r.l. for the production of a next-generation highly selective and brain-penetrant PARP1 inhibitor. Such developments are contributing to the increasing demand for PARP inhibitors across the world.
Our in-depth analysis of the DNA repair drugs market includes the following segments:
|
Drug Type |
|
|
Application |
|
|
Distribution Channel |
|
North America Market Forecast
By 2037, North America DNA repair drugs market is anticipated to capture over 47.5% share owing to the rising burden of cancer and the increasing number of investments in the research and development of DNA repair drugs. For instance, according to the American Cancer Society, in 2024, more than 20 lakh new cancer cases are estimated to be detected in the U.S.
The U.S. DNA repair drugs market is expected to exhibit high growth throughout the forecasted period due to the rising personalized medication trend. Manufacturers in the country are focused on developing therapeutic approaches based on individual genetic profiles that can specifically address genetic mutations and repair mechanisms.
Canada is also an opportunistic for DNA repair drugs market, several research institutions in the country are focused on developing effective solutions. For instance, researchers from Toronto revealed human DNA repair by nuclear metamorphosis. To explore this mechanism over 8,500 cancer patient’s data was analysed by them.
APAC Market Statistics
Asia Pacific DNA repair drugs market is expected to increase at a fast pace during the forecast period owing to rapid advancements in healthcare infrastructure. Countries such as India, China, and Japan are spending more on advancing their healthcare facilities and innovation in drug development. The increasing awareness of chronic disorders and treatment solutions is also expected to fuel the sales of DNA repair drugs in the region.
India is emerging as a lucrative DNA repair drugs market for pharma companies owing to positive government support and policies. For instance, according to estimates by the India Brand Equity Foundation, the pharma market in India is anticipated to reach USD 130 billion by 2030. As per the same source, in December 2020, an MoU was signed between the Tata Memorial Centre of India and Vietnam National Cancer Hospital to promote exchanges in the field of healthcare services, training and scientific research, and collaboration in the diagnosis and treatment of cancer patients. Such initiatives are set to fuel the sales of DNA repair drugs in the country.
The DNA repair drugs market is competitive due to the existence of industry giants and the entrance of new companies. The key market players are adopting strategies such as collaborations and partnerships to introduce innovative therapeutic solutions and increase their market reach. Collaboration with research organizations is one of the investment-worthy tactics widely adopted by leading companies. New companies are concentrated on introducing advanced and latest DNA repair cancer drugs. Such moves are widely adopted by start-ups to stand out from the crowd.
Some of the key players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?